[go: up one dir, main page]

WO2024256358A2 - Marquage accéléré de 5-formyl cytosine et utilisation dans le séquençage de méthylation d'acide nucléique - Google Patents

Marquage accéléré de 5-formyl cytosine et utilisation dans le séquençage de méthylation d'acide nucléique Download PDF

Info

Publication number
WO2024256358A2
WO2024256358A2 PCT/EP2024/066001 EP2024066001W WO2024256358A2 WO 2024256358 A2 WO2024256358 A2 WO 2024256358A2 EP 2024066001 W EP2024066001 W EP 2024066001W WO 2024256358 A2 WO2024256358 A2 WO 2024256358A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
nucleic acid
bipyridine
chelator
acid molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/066001
Other languages
English (en)
Other versions
WO2024256358A3 (fr
Inventor
Shwu shin CHANG
Peter CRISTALLI
Omid KHAKSHOOR
David Lawrence PENKLER
Jo-Anne Elizabeth PENKLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Roche Sequencing Solutions Inc
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Roche Sequencing Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH, Roche Sequencing Solutions Inc filed Critical F Hoffmann La Roche AG
Publication of WO2024256358A2 publication Critical patent/WO2024256358A2/fr
Publication of WO2024256358A3 publication Critical patent/WO2024256358A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Definitions

  • the present disclosure relates to the field of nucleic acid-based diagnostics. More specifically, the invention related to a method of detecting epigenetic modifications in nucleic acid molecules, wherein the epigenetic modifications may have biological and clinical significance.
  • DNA methylation plays a major role in regulating various physiological and pathological processes in mammals.
  • DNA methylation is an important epigenetic event in modulating embryonic development, genomic imprinting, X inactivation, cellular differentiation, and proliferation. Abnormal patterns of DNA methylation, however, are correlated with DNA instability and will ultimately trigger a subsequent heritage or required diseases such as cancer, though increasingly DNA methylation is being reported as a potential biomarker for other psychiatric and metabolic diseases as well.
  • DNA methylation primarily occurring at the C5 position within the cytosine ring within cytosine-guanine (CpG) dinucleotides, is frequently found clustered at gene regulatory sites such as promoter regions.
  • Dense methylation of CpGs in the gene promoter region is associated with a compacted chromatin structure resulting in transcriptional silencing of the affiliated gene. If DNA hypermethylation occurs at the promoter regions of certain critical cancer-related genes, it could lead to tumor suppressor gene silencing and ultimately tumorigenesis. It is believed that DNA methylation changes are present and detectable in tumors and in blood. Therefore, aberrant DNA methylation of specific oncogenes may be regarded as biomarkers for the early diagnosis of cancer.
  • Bisulfite genomic sequencing provides a qualitative, quantitative, and efficient approach to identify 5-methylcytosine at single base-pair resolution. This method is based on the finding that the deamination reactions of cytosine and 5- methylcytosine (5-mC) proceed with very different consequences after the treatment of sodium bisulfite.
  • target nucleic acids are first treated with bisulfite reagents that specifically convert un-methylated cytosines to uracil residues while having no impact of methylated cytosine.
  • uracil residues are then recognized as thymine in subsequent PCR amplification and sequencing, however, 5-mCs are immune to this conversion and remain as cytosines allowing 5-mCs to be distinguished from unmethylated cytosines.
  • a subsequent PCR process is necessary to determine the methylation status in the loci of interest by using specific methylation primers after the bisulfite treatment.
  • the actual methylation status can be determined either through direct PCR product sequencing (e.g., detection of average methylation status) or subcloning sequencing (e.g., detection of single molecule distribution of methylation patterns).
  • bisulfite sequencing analysis can not only identify DNA methylation status along the DNA single strand, but also detect the DNA methylation patterns of DNA double strands since the converted DNA strands are no longer self- complementary and the amplification products can be measured individually.
  • bisulfite treatment leads to degradation of a large portion of sample DNA.
  • one unwanted consequence of bisulfite conversion is that the double-stranded conformation of the original target is disrupted due to loss of sequence complementarity.
  • bisulfite conversion can be incomplete unless it is done for long durations at high temperatures, and this can often degrade up to about 95% of the DNA input.
  • bisulfite methods do not distinguish between 5-mC and the closely related 5- hydroxymethyl cytosine (5-hmC), another potential epigenetic biomarker.
  • TAPS TET-assisted pyridine-borane sequencing
  • oxidation products can be reacted with malononitrile to form an adduct also read as T during sequencing, see Zhu C., et al., (2017) Single-Cell 5-Formylcytosine Landscapes of Mammalian Early Embryos and ESCs at Single-Base Resolution, Cell Stem Cell, 20:720-731. e5.
  • Malononitrile reacts exclusively with 5-formyl cytosine (5-fC). See also United States Patent No. 10,519,184.
  • Malononitrile adduct of 5-formyl cytosine acts like a thymidine nucleotide and can be differentiated from cytosines.
  • the formation of the malononitrile adduct of 5-formyl cytosine is, however, time consuming, taking from 12 - 36 hours, thus elongating the processing time needed for the preparation of sequencing samples.
  • Applicant has discovered that copper salts can be utilized to accelerate the addition of malononitrile or like compounds to 5-formyl cytosine.
  • Applicant has unexpectedly discovered that a combination of a copper salt and a chelator selected from one of a bipyridine or a phenanthroline allowed for the efficient formation of adducts of 5-formyl cytosine in both single stranded and double stranded nucleic acid molecules in less than about 1 hour and at temperatures lower than that required by prior art methods.
  • adduct of 5-formyl cytosine may be performed efficiently with highly basic and denatured samples (e.g., those including about 10 to about 20 mM of NaOH) or with slightly alkaline samples including buffers (e.g., those including about 10 mM of TRIS at about pH 8). Additionally, Applicant has surprisingly discovered that adducts of 5-formyl cytosine may be formed from 5- hydroxymethyl cytosine in a "one pot" synthesis within about 3 hours, such as within about 2 hours, without requiring any purification of any intermediates.
  • a first aspect of the present disclosure is a composition comprising: (a) one or more nucleic acid molecules each having one or more 5-formyl cytosine bases, (b) a copper salt, (c) a chelator selected from one of a bipyridine or a phenanthroline, and (d) a compound having Formula (I): (i),
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl; and
  • composition has a pH ranging from about 7 to about 12.
  • R is cyano, nitro, Ci-Ce alkyl, carboxylic ester.
  • R is cyano or Ci-Ce alkyl.
  • the compound of Formula (I) is malononitrile.
  • the chelator is a phenanthroline. In some embodiments, the chelator is a bipyridine.
  • the copper salt is complexed with the chelator.
  • a ratio of the copper salt to the chelator within the composition ranges from between about 1 :3 to about 1 : 1.75.
  • a ratio of the copper salt to the chelator within the composition is about 1 :2.75.
  • a ratio of the copper salt to the chelator within the composition is about 1 :2.5.
  • a ratio of the copper salt to the chelator within the composition is about 1 :2.25.
  • the chelator is a 2,2'-bipyridine or a derivative thereof.
  • the derivative of 2,2' -bipyridine is selected from the group consisting of 4,4'-dimethyl-2,2'-bipyridine, 5,5'-dimethyl-2,2'-bipyridine 4,4'- diethyl-2,2'-bipyridine, 5,5'-diethyl-2,2'-bipyridine, 4,4'-dimethoxy-2,2'-bipyridine, [0017]
  • the copper salt is selected from the group consisting of Cu(ClC>4)2, CuSC>4, Cu(ACN)4 triflate, and Cu(OAc)2.
  • the copper salt is (Cu(ClC>4)2 and the chelator is a 2,2'-bipyridine.
  • the one or more nucleic acid molecules are single stranded. In some embodiments, the one or more nucleic acid molecules are double stranded. In some embodiments, the pH ranges from between about 8 to about 12. In some embodiments, the composition further comprises an N-oxide reagent.
  • a second aspect of the present disclosure is a composition
  • a composition comprising: (a) one or more nucleic acid molecules each having one or more 5- hydroxymethyl cytosine bases, (b) a copper salt, (c) a chelator selected from the group consisting of a bipyridine or a phenanthroline, and (d) an N-oxide reagent, wherein the composition has a pH ranging from about 7 to about 12, wherein the N- oxide reagent is selected from the group consisting of ABNO, AZADO, and Me- AZADO.
  • the copper salt is complexed with the chelator.
  • a ratio of the copper salt to the chelator within the composition ranges from between about 1 :3 to about 1 : 1. In some embodiments, a ratio of the copper salt to the chelator within the composition is about 1:2.5. In some embodiments, a ratio of the copper salt to the chelator within the composition is about 1 :2.2. In some embodiments, a of the copper salt to the chelator within the composition is about 1 :2.
  • the chelator is a 2,2'-bipyridine or a derivative thereof.
  • the bipyridine is selected from the group consisting of 4,4'-dimethyl-2,2'-bipyridine, 5,5'-dimethyl-2,2'-bipyridine, 4,4'-diethyl-2,2'- bipyridine, 5,5'-diethyl-2,2'-bipyridine, 4,4'-dimethoxy-2,2'-bipyridine, and 5,5'- dimethoxy-2,2'-bipyridine.
  • the N-oxide reagent in the copper salt is selected from the group consisting of Cu(C104)2, CuSCh, Cu(ACN)4 triflate, and Cu(OAc)2.
  • the N-oxide reagent is AZADO.
  • the N-oxide reagent is Me-AZADO.
  • the N-oxide reagent comprises ABNO.
  • a ratio of the copper salt to the N-oxide within the composition ranges from about 1 :0.5 to about 1 :0.1. In some embodiments, a ratio of the copper salt to the N-oxide within the composition is about 1 :0.2.
  • the composition further comprises a solvent.
  • the solvent is acetonitrile.
  • the composition comprises a base selected from the group consisting of NaOH, KOH, and LiOH.
  • the composition comprises TRIS, TAPSO, TEA, EPPS, Tricine, Gly-Gly, Bicine, TABS, AMPSO, CHES, CAPSO, AMP, CAPS.
  • the pH of the composition ranges from between about 8 to about 12.
  • the one or more nucleic acid molecules are single stranded. In some embodiments, the one or more nucleic acid molecules are double stranded.
  • a third aspect of the present disclosure is a method for preparing one or more nucleic acid molecules each having one or more 5-formyl cytosine bases, comprising: (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5 -hydroxymethyl cytosine bases; and (b) reacting the obtained sample with a first composition comprising a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide reagent, wherein the N-oxide reagent is selected from the group consisting of ABNO, AZADO, and Me- AZADO.
  • the first composition further comprises at least one of a base or buffer.
  • the reaction occurs at a pH ranging from between about 7 to about 12.5. In some embodiments, the reaction occurs at a pH ranging from between about 8 to about 12. In some embodiments, the reaction occurs at a temperature ranging from between about 20°C to about 35°C. In some embodiments, the temperature ranges from between about 20°C to about 30°C. In some embodiments, the temperature ranges from between about 25°C to about 30°C. In some embodiments, the reaction occurs for a time period ranging from between about 30 minutes to about 90 minutes. In some embodiments, the time period is about 60 minutes.
  • a ratio of the copper salt to the chelator within the first composition is about 1 :2.75. In some embodiments, a ratio of the copper salt to the chelator within the first composition is about 1 :2.5. In some embodiments, a ratio of the copper salt to the chelator within the first composition is about 1 :2.25. In some embodiments, the chelator is a 2,2'-bipyridine or a derivative thereof.
  • the bipyridine is selected from the group consisting of 4, d'dimethyl ⁇ , 2'-bipyri dine, 5,5'-dimethyl-2,2'-bipyridine, 4,4'-diethyl-2,2'-bipyridine, 5,5'-diethyl-2,2'-bipyridine, 4,4'-dimethoxy-2,2'-bipyridine, 5,5'-dimethoxy-2,2'- bipyridine.
  • the copper salt is selected from the group consisting of Cu(ClC>4)2, CuSC>4, Cu(ACN)4 tritiate, and Cu(OAc)2.
  • the N-oxide is ABNO.
  • the copper salt is Cu(ACN)4 tritiate or Cu(OAc)2; the chelator is a 2,2'-bipyridine; and the N-oxide is ABNO.
  • the method further comprises monitoring the reaction by liquid chromatography and/or mass spectroscopy. In some embodiments, the method further comprises performing at least one additional downstream reaction following the reaction between the obtained sample and the first composition. In some embodiments, the at least one additional downstream reaction comprises converting the 5-formyl cytosine bases in the one or more nucleic acid molecules to an adduct of 5-formyl cytosine, thereby producing one or more nucleic acid molecules having one or more adducts of 5-formyl cytosine. In some embodiments, the adduct of 5-formyl cytosine is a malononitrile adduct of 5-formyl cytosine.
  • the method further comprises contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with a polymerase to provide one or more amplified nucleic acid molecules, wherein the one or more amplified nucleic acid molecules have a thymine base at a position corresponding to the position of the adduct of 5-formyl cytosine in each of the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine.
  • the method further comprises sequencing the one or more amplified nucleic acid molecules.
  • the sequencing comprises next-generation sequencing.
  • a fourth aspect of the present disclosure is a method for preparing one or more nucleic acid molecules each having one or more adducts of 5-formyl cytosine, comprising: (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5-formyl cytosine bases; and (b) reacting the obtained sample with a composition comprising a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and a compound having Formula (I): [0033] where
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl.
  • R is cyano or Ci-Ce alkyl.
  • the compound of Formula (I) is malononitrile.
  • the reaction occurs at a pH ranging from between about 7 to about 12.5. In some embodiments, the reaction occurs at a pH ranging from between about 8 to about 12. In some embodiments, the reaction occurs at a temperature ranging from between about 20°C to about 35°C. In some embodiments, the temperature ranges from between about 20°C to about 30°C. In some embodiments, the temperature ranges from between about 25°C to about 30°C. In some embodiments, the reaction occurs for a time period ranging from between about 30 minutes to about 90 minutes. In some embodiments, the time period is about 60 minutes.
  • the chelator is a phenanthroline. In some embodiments, the chelator is a bipyridine. In some embodiments, a ratio of the copper salt to the chelator within the first composition is about 1 :2.75. In some embodiments, a ratio of the copper salt to the chelator within the first composition is about 1 :2.5. In some embodiments, a ratio of the copper salt to the chelator within the first composition is about 1 :2.25. In some embodiments, the chelator is a 2,2'- bipyridine or a derivative thereof.
  • the bipyridine is selected from the group consisting of 4,4'-dimethyl-2,2'-bipyridine, 5,5'-dimethyl-2,2'- bipyridine, 4,4'-diethyl-2,2'-bipyridine, 5,5'-diethyl-2,2'-bipyridine, 4,4'-dimethoxy- 2,2'-bipyridine, and 5,5'-dimethoxy-2,2'-bipyridine.
  • the copper salt is selected from the group consisting of Cu(C104)2, CuSCh, Cu(ACN)4 triflate, and Cu(OAc)2.
  • the method further comprises monitoring the reaction by liquid chromatography and/or mass spectroscopy.
  • the method further comprises contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with a polymerase to provide one or more amplified nucleic acid molecules, wherein the one or more amplified nucleic acid molecules have a thymine base at a position corresponding to the position of the adduct of 5-formyl cytosine in each of the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine.
  • the method further comprises sequencing the one or more amplified nucleic acid molecules.
  • the sequencing comprises next-generation sequencing.
  • the obtained sample is prepared by: (i) obtaining a solution comprising one or more nucleic acid molecules each having one or more 5 -hydroxymethyl cytosine bases; and (ii) oxidizing the 5 -hydroxymethyl cytosine bases of the one or more nucleic acid molecules in the solution to provide the sample comprising the one or more nucleic acid molecules each having one or more 5-formyl cytosine bases.
  • the oxidizing comprises exposing the solution to a formulation comprising a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide.
  • a fifth aspect of the present disclosure is a method for synthesizing one or more nucleic acid molecules each comprising one or more adducts of 5-formyl cytosine, the method comprising: (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5 -hydroxymethyl cytosine bases; (b) contacting the obtained sample with a first composition at a first temperature and for a first time period to provide a mixture comprising one or more nucleic acid molecules each having one or more 5-formyl cytosine bases, wherein the first composition comprises a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide reagent; and (c) contacting the resulting mixture with a second composition at a second temperature for a second time period, wherein the second composition comprises a compound having Formula (I): (i),
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl,
  • nucleic acid molecules each comprising the one or more adducts of 5-formyl cytosine.
  • the resulting mixture is contacted with the second composition without first purifying the resulting mixture.
  • the obtained sample is contacted with the first composition at a pH ranging from between about 8 and about 12.
  • the obtained sample is contacted with the second composition at a pH ranging from between about 8 and about 12.
  • the first temperature ranges from between about 20°C to about 35°C.
  • the second temperature ranges from between about 20°C to about 35°C.
  • the first and second temperatures are about the same.
  • the first duration is between about 30 minutes and about 90 minutes; and wherein the second duration is between about 30 minutes and about 90 minutes.
  • the copper salt is Cu(ACN)4 triflate or CU(OAC)2; and the chelator is a 2,2'-bipyridine.
  • a ratio of an amount of the Cu(ACN)4 triflate or the Cu(OAc)2 to an amount of the 2,2'-bipyridine present in the first composition ranges from between about 1 : 1 to about 1 :3.
  • the compound having Formula (I) is malononitrile.
  • the bipyridine is selected from the group consisting of 4,4'-dimethyl-2,2'-bipyridine, 5,5'-dimethyl-2,2'-bipyridine, 4,4'- diethyl-2,2'-bipyridine, 5,5'-diethyl-2,2'-bipyridine, 4,4'-dimethoxy-2,2'-bipyridine, and 5,5'-dimethoxy-2,2'-bipyridine.
  • the one or more nucleic acid molecules in the obtained sample are single stranded nucleic acid molecules. In some embodiments, the one or more nucleic acid molecules in the obtained sample are double stranded nucleic acid molecules. In some embodiments, the one or more nucleic acid molecules in the obtained sample are ligated to one or more adapters. In some embodiments, the one or more nucleic acid molecules in the obtained sample include one or more barcodes. In some embodiments, the one or more barcodes are unique molecular identifiers.
  • the obtained sample is prepared by: (i) obtaining a solution comprising one or more nucleic acid molecules each having one or more 5-methyl cytosine bases; and (ii) oxidizing the 5-methyl cytosine bases of the one or more nucleic acid molecules in the solution to provide the sample comprising the one or more nucleic acid molecules each having one or more 5- hydroxymethyl cytosine bases.
  • the method further comprises contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with a polymerase to provide one or more amplified nucleic acid molecules, wherein the one or more amplified nucleic acid molecules have a thymine base at a position corresponding to the position of the adduct of 5-formyl cytosine in each of the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine.
  • the adduct of 5-formyl cytosine is a malononitrile adduct of 5-formyl cytosine.
  • the method further comprises ligating one or more adapters to the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine prior to contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with the polymerase.
  • polymerase is a DNA polymerase.
  • the DNA polymerase is an uracil-tolerant polymerase.
  • the method further comprises sequencing the one or more amplified nucleic acid molecules.
  • the sequencing comprises next-generation sequencing.
  • the obtained sample is obtained from a tumor. In some embodiments, the obtained sample is obtained from a specimen suspected of having a tumor.
  • kits comprising: (i) a first container including a copper salt and a chelator selected from one of a bipyridine or a phenanthroline; and (n) a second container including a polymerase.
  • the kit further comprises a third container including an adduct forming reagent having Formula (I), (i),
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl.
  • a ratio of an amount of chelator to an amount of copper salt in the first container ranges from about 2: 1.
  • the polymerase is a thermostable polymerase.
  • the kit further comprises at least one of a buffer or a strong base.
  • a seventh aspect of the present disclosure is a method for detecting one or more epigenetic changes in a target nucleic acid molecule, comprising: (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5 -hydroxymethyl cytosine bases; (b) contacting the obtained sample with a first composition at a first temperature and for a first time period to provide a mixture comprising one or more nucleic acid molecules each having one or more 5-formyl cytosine bases, wherein the first composition comprises a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide reagent; (c) contacting the resulting mixture with a second composition at a second temperature for a second time period, wherein the second composition comprises a compound having Formula (I): (i),
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl,
  • nucleic acid molecules each comprising the one or more adducts of 5 -formyl cytosine; (d) contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with a polymerase to provide one or more amplified nucleic acid molecules, wherein the one or more amplified nucleic acid molecules have a thymine base at a position corresponding to the position of the adduct of 5-formyl cytosine in each of the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine; and (e) sequencing the one or more amplified nucleic acid molecules.
  • the adduct of 5-formyl cytosine is a malononitrile adduct of 5-formyl cytosine.
  • the method further comprises ligating one or more adapters to the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine prior to contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with the polymerase.
  • the polymerase is a DNA polymerase.
  • the DNA polymerase is an uracil-tolerant polymerase.
  • the sequencing comprises next-generation sequencing.
  • FIG. 1 provides LC-MS traces of the conversion of a 5-formyl cytosine nucleotide in a nucleic acid molecule to its respective malononitrile adduct under different reaction conditions.
  • FIG. 2 provides LC-MS traces of the conversion of a 5-formyl cytosine nucleotide in a nucleic acid molecule to its respective malononitrile adduct under different reaction conditions.
  • FIG. 3 provides LC-MS traces of the conversion of a 5-formyl cytosine nucleotide in a nucleic acid molecule to its respective malononitrile adduct under different reaction conditions.
  • FIG. 4 provides LC-MS traces of the conversion of a 5-formyl cytosine nucleotide in a nucleic acid molecule to its respective malononitrile adduct under different reaction conditions.
  • FIG. 5 sequencing data of the conversion rate of oligo containing a single 5-formyl cytosine base treated with standard malononitrile in Tris compared to Cu2+/2,2'-bipyridine complex added with lOOmM malononitrile.
  • FIG. 6 provides an LC-MS trace of the conversion of a 5- hydroxymethyl cytosine nucleotide in a nucleic acid molecule to its respective malononitrile adduct in a tandem reaction.
  • a method involving steps a, b, and c means that the method includes at least steps a, b, and c.
  • steps and processes may be outlined herein in a particular order, the skilled artisan will recognize that the ordering steps and processes may vary.
  • the phrase "at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
  • At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
  • an adapter refers to a nucleotide sequence that may be added to another sequence so as to import additional properties to that sequence.
  • An adapter can be single- or double-stranded or may have both a singlestranded portion and a double-stranded portion.
  • amplification refers to a process in which a copy number increases. Amplification may be a process in which replication occurs repeatedly over time to form multiple copies of a template. Amplification can produce an exponential or linear increase in the number of copies as amplification proceeds. Exemplary amplification strategies include polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), rolling circle replication (RCA), cascade-RCA, nucleic acid-based amplification (NASBA), and the like. Also, amplification can utilize a linear or circular template. Amplification can be performed under any suitable temperature conditions, such as with thermal cycling or isothermally.
  • PCR polymerase chain reaction
  • LAMP loop-mediated isothermal amplification
  • RCA rolling circle replication
  • NASBA nucleic acid-based amplification
  • amplification can utilize a linear or circular template. Amplification can be performed under any suitable temperature conditions, such as with thermal cycling or isothermally.
  • amplification can be performed in an amplification mixture (or reagent mixture), which is any composition capable of amplifying a nucleic acid target, if any, in the mixture.
  • PCR amplification relies on repeated cycles of heating and cooling (i.e., thermal cycling) to achieve successive rounds of replication.
  • PCR can be performed by thermal cycling between two or more temperature setpoints, such as a higher denaturation temperature and a lower annealing/extension temperature, or among three or more temperature setpoints, such as a higher denaturation temperature, a lower annealing temperature, and an intermediate extension temperature, among others.
  • PCR can be performed with a thermostable polymerase, such as Taq DNA polymerase.
  • PCR produces an exponential increase in the amount of a product amplicon over successive cycles.
  • PCR is described, for example, in U.S. Pat. No. 4,683,202; U.S. Pat. No. 4,683,195; U.S. Pat. No. 4,000,159; U.S. Pat. No. 4,965,188; U.S. Pat. No. 5,176,995), the disclosures of each are hereby incorporated by reference herein in their entirety.
  • biological sample refers to any sample including a biomolecule (such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof) that is obtained from any organism including viruses.
  • a biomolecule such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof
  • Other examples of organisms include mammals (such as humans; veterinary animals like cats, dogs, horses, cattle, and swine; and laboratory animals like mice, rats, and primates), insects, annelids, arachnids, marsupials, reptiles, amphibians, bacteria, and fungi.
  • biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (for example, obtained by a surgical biopsy or a needle biopsy), nipple aspirates, cerumen, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.
  • the term "biological sample” as used herein refers to a sample (such as a homogenized or liquefied sample) prepared from a tumor or a portion thereof obtained from a subject.
  • Ca to Cb in which "a” and “b” are integers refer to the number of carbon atoms in an alkyl, alkenyl or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, cycloalkenyl, cycloalkynyl or aryl group, or the total number of carbon atoms and heteroatoms in a heteroalkyl, heterocyclyl, heteroaryl or heteroalicyclyl group.
  • the alkyl, alkenyl, alkynyl, ring of the cycloalkyl, ring of the cycloalkenyl, ring of the cycloalkynyl, ring of the aryl, ring of the heteroaryl or ring of the heteroalicyclyl can contain from "a" to "b", inclusive, carbon atoms.
  • a "Ci to C4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH3 — , CH3CH2 — , CH3CH2CH2 — , (CH3)2CH — , CH3CH2CH2CH2, CH 3 CH 2 CH(CH3)— and (CH 3 ) 3 C— . If no "a” and "b” are designated with regard to an alkyl, alkenyl, alkynyl, cycloalkyl cycloalkenyl, cycloalkynyl, aryl, heteroaryl or heteroalicyclyl group, the broadest range described in these definitions is to be assumed.
  • alkyl includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tertbutyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • straight-chain alkyl groups e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc
  • a derivative is used in accordance with its plain ordinary meaning within chemistry and biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, a derivative is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
  • next-generation sequencing technology uses clonal amplification and sequencing by synthesis (SBS) chemistry to enable rapid sequencing.
  • SBS sequencing by synthesis
  • the process simultaneously identifies DNA bases while incorporating them into a nucleic acid chain. Each base emits a unique fluorescent signal as it is added to the growing strand, which is used to determine the order of the DNA sequence.
  • a non-limiting example of a sequencing device available from ThermoFisher Scientific (Waltham, MA) includes the Ion Personal Genome MachineTM (PGMTM) System.
  • Ion Torrent sequencing measures the direct release of H+ (protons) from the incorporation of individual bases by DNA polymerase.
  • a non-limiting example of a sequencing device available from Pacific Biosciences (Menlo Park, CA) includes the PacBio Sequel Systems.
  • a non-limiting example of a sequencing device available from Roche (Pleasanton, CA) is the Roche 454.
  • Nextgeneration sequencing methods may also include nanopore sequencing methods.
  • strand sequencing in which the bases of DNA are identified as they pass sequentially through a nanopore
  • exonuclease-based nanopore sequencing in which nucleotides are enzymatically cleaved one-by-one from a DNA molecule and monitored as they are captured by and pass through the nanopore
  • SBS nanopore sequencing by synthesis
  • Strand sequencing requires a method for slowing down the passage of the DNA through the nanopore and decoding a plurality of bases within the channel; ratcheting approaches, taking advantage of molecular motors, have been developed for this purpose.
  • Exonuclease-based sequencing requires the release of each nucleotide close enough to the pore to guarantee its capture and its transit through the pore at a rate slow enough to obtain a valid ionic current signal.
  • both methods rely on distinctions among the four natural bases, two relatively similar purines and two similar pyrimidines.
  • sequencing of nucleic acid molecules via nanopore sequencing comprises preparing nanopore sequencing complexes and determining polynucleotide sequences. Methods of preparing nanopores and nanopore sequencing are described in U.S. Patent Application Publication No. 2017/0268052, and PCT Publication Nos. WO2014/074727, W02006/028508, WO2012/083249, and WO/2014/074727, the disclosures of which are hereby incorporated by reference herein in their entireties.
  • tagged nucleotides may be used in the determination of the polynucleotide sequences (see, e.g., PCT Publication No. WO/2020/131759, WO/2013/191793, and WO/2015/148402, the disclosures of which are hereby incorporated by reference herein in their entireties).
  • Analysis of the data generated by sequencing is generally performed using software and/or statistical algorithms that perform various data conversions, e.g., conversion of signal emissions into base calls, conversion of base calls into consensus sequences for a nucleic acid template, etc.
  • data conversions e.g., conversion of signal emissions into base calls, conversion of base calls into consensus sequences for a nucleic acid template, etc.
  • Such software, statistical algorithms, and the use of such are described in detail, in U.S. Patent Application Publication Nos. 2009/0024331 2017/0044606 and in PCT Publication No. WO/2018/034745, the disclosures of which are hereby incorporated by reference herein in their entireties.
  • the "polymerase” as used herein refers to an enzyme that catalyzes the process of replication of nucleic acids. More specifically, DNA polymerase catalyzes the polymerization of deoxyribonucleotides alongside a DNA strand, which the DNA polymerase "reads” and uses as a template. The newly polymerized molecule is complementary to the template strand and identical to the template's partner strand.
  • sequencing refers to the determination of the order and position of bases in a nucleic acid molecule. More particularly, the term “sequencing” refers to biochemical methods for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, in a DNA oligonucleotide. Sequencing, as the term is used herein, can include without limitation parallel sequencing or any other sequencing method known of those skilled in the art, for example, chain-termination methods, rapid DNA sequencing methods, wandering-spot analysis, Maxam-Gilbert sequencing, dye- terminator sequencing, or using any other modern automated DNA sequencing instruments.
  • the present disclosure provides compositions for converting 5- hydroxymethyl cytosine bases in target nucleic acid molecules to 5-formyl cytosine bases.
  • the present disclosure also provides compositions for converting 5-formyl cytosine bases in target nucleic acid molecules to the respective adduct of 5-formyl cytosine, such as a malononitrile adduct of 5-formyl cytosine.
  • Each of the compositions of the present disclosure utilize a mixture of a copper salt and a chelator selected from one of a bipyridine or a phenanthroline.
  • the "one pot" synthetic method of the present disclosure does not require any purification of any intermediates, allowing for nucleic acid libraries to be built rapidly. Additionally, the "one pot” synthetic method is quick, allowing for formation of the 5-formyl cytosine adduct within about three hours or less, such as within about two hours or less, such as within about 90 minutes or less, etc.
  • the present disclosure also provides for methods of detecting epigenetic modifications in a target nucleic acid molecule, such as those epigenetic modifications characterized by methylation of cytosine at the 5-position position (e.g., 5-methyl cytosine; 5 -hydroxymethyl cytosine).
  • the methods of detecting the epigenetic modifications comprises converting those cytosine bases in a nucleic acid molecule characterized by a methylation at the 5- position to an adduct of 5-formyl cytosine, followed by amplification of the nucleic acid molecule including the adduct of 5-formyl cytosine in the presence of a polymerase, wherein the polymerase reads the one or more adducts of 5-formyl cytosine as thymine during amplification.
  • the amplification product may then be sequenced, such as with next-generation sequencing. Diagnostic decisions may then be made based on the data from the sequencing.
  • one or more adapters are ligated to the nucleic acid molecule prior to amplification, wherein the adapters may include one or more molecular barcodes, one or more multiplex identifiers (MIDs), and/or one or more unique molecular identifier (UIDs).
  • Amplification of the nucleic acid molecule including the one or more adducts of 5-formyl cytosine in the presence of a polymerase causes the polymerase to read the one or more adducts of 5-formyl cytosine as a thymine.
  • the amplified target nucleic acid molecule may then be sequenced, such as with a next-generation sequencing technique.
  • compositions for use in preparing target nucleic acid molecules including one or more 5-formyl cytosine bases or adducts of 5-formyl cytosine.
  • the compositions of the present disclosure include components selected from: target nucleic acid molecules, copper salts, a chelator selected from one of a bipyridine or a phenanthroline, N- oxide reagents, adduct forming reagents, bases, buffers, solvents, etc.
  • the compositions of the present disclosure include one or more target nucleic acid molecules derived from a biological sample.
  • the target nucleic acid molecules include one or more 5- hydroxymethyl cytosine bases.
  • the target nucleic acid molecules include one or more 5-formyl cytosine bases.
  • the target nucleic acid molecules are single stranded and include one or more 5-formyl cytosine (5-fC) bases such as one 5-formyl cytosine base, such as two 5- hydroxymethylcytosine bases, such three 5-formyl cytosine bases, such as four 5- formyl cytosine bases, such as 5 or more 5-formyl cytosine bases.
  • 5-fC 5-formyl cytosine
  • the target nucleic acid molecules are double stranded.
  • the target nucleic acid molecules are double stranded and include one or more 5-hydroxymethylcytosine bases, such as one 5- hydroxymethylcytosine base, such as two 5-hydroxymethylcytosine bases, such three 5-hydroxymethylcytosine bases, such as four 5-hydroxymethylcytosine bases, such as 5 or more 5-hydroxymethylcytosine bases.
  • the target nucleic acid molecules are double stranded and include one or more 5-formyl cytosine bases such as one 5-formyl cytosine base, such as two 5- hydroxymethylcytosine bases, such three 5-formyl cytosine bases, such as four 5- formyl cytosine bases, such as 5 or more 5-formyl cytosine bases.
  • the 5-hydroxymethylcytosine bases are on one or both strands of the double stranded target nucleic acid molecule.
  • samples may be obtained from any source including a target nucleic acid sequence having one or more cytosine residues of interest, e.g., tissue (including tumor tissue or FFPE tissue), blood, skin, swab (e.g., buccal, vaginal), urine, saliva, etc.
  • tissue including tumor tissue or FFPE tissue
  • swab e.g., buccal, vaginal
  • urine saliva
  • the sample is derived from a subject or a patient.
  • the sample may comprise a fragment of a solid tissue or a tumor sample derived from the subject or the patient, e.g., by biopsy.
  • tumor sample encompasses samples prepared from a tumor or from a sample potentially comprising or suspected of comprising cancer cells, or to be tested for the potential presence of cancer cells, such as a lymph node.
  • tumor refers to a mass or a neoplasm, which itself is defined as an abnormal new growth of cells that usually grow more rapidly than normal cells and will continue to grow if not treated, sometimes resulting in damage to adjacent structures. Tumor sizes can vary widely.
  • a tumor may be solid, or fluid filled.
  • a tumor can refer to benign (not malignant, generally harmless), or malignant (capable of metastasis) growths.
  • tumors can contain neoplastic cells that are benign (such as carcinoma in situ) and, simultaneously, contain malignant cancer cells (such as adenocarcinoma). This should be understood to include neoplasms located in multiple locations throughout the body. Therefore, for purposes of the disclosure, tumors include primary tumors, lymph nodes, lymphatic tissue, and metastatic tumors.
  • nucleic acid molecules may be isolated from biological samples using any of a variety of procedures known in the art, for example, MagMAXTM DNA Multi-Sample Ultra Kit (Applied Biosystems, Thermo Fisher Scientific), the MagMAXTM Express-96 Magnetic Particle Processor and the KingFisherTM Flex Magnetic Particle Processor (Thermo Fisher Scientific), a RecoverAllTM Total Nucleic Acid Isolation Kit for FFPE and PureLinkTM FFPE RNA Isolation Kit (AmbionTM, Thermo Fisher Scientific), the ABI PrismTM 6100 Nucleic Acid PrepStation and the ABI PrismTM 6700 Automated Nucleic Acid Workstation (Applied Biosystems, Thermo Fisher Scientific), and the like. It will be appreciated that nucleic acid molecules from the biological samples may be cut or sheared prior to analysis, including the use of such procedures as mechanical force, sonication, restriction endonuclease cleavage, or any method known in the art.
  • the target nucleic acid molecules have a length ranging from between about 10 mer to about 5000 mer. In some embodiments, the target nucleic acid molecules have a length ranging from between about 10 mer to about 2500 mer. In some embodiments, the target nucleic acid molecules have a length ranging from between about 10 mer to about 2000 mer. In some embodiments, the target nucleic acid molecules have a length ranging from between about 10 mer to about 1000 mer. In some embodiments, the target nucleic acid molecules have a length ranging from between about 10 mer to about 500 mer. In some embodiments, the target nucleic acid molecules have a length ranging from between about 10 mer to about 250 mer.
  • the target nucleic acid molecules have a length ranging from between about 15 mer to about 150 mer. In yet other embodiments, the target nucleic acid molecules have a length ranging from between about 15 mer to about 100 mer. In further embodiments, the target nucleic acid molecules have a length ranging from between about 15 mer to about 60 mer.
  • the target nucleic acid molecule includes at least one analog of cytosine per strand, e.g., one or more 5 -hydroxymethyl cytosines or one or more 5-formyl cytosines. In some embodiments, the target nucleic acid molecule includes at least two analogs of cytosine per strand. In some embodiments, the target nucleic acid molecule includes at least three analogs of cytosines per strand. In some embodiments, the target nucleic acid molecule includes at least four analogs of cytosines per strand.
  • the compositions of the present disclosure include one or more copper salts.
  • the copper salt may be any salt of copper in any of its common oxidation states, including cuprous salts, Cu(I), and cupric salts, Cu(II).
  • the copper salt is selected from a copper halide, a copper nitrate, a copper acetate, a copper sulfate, copper formate, and copper oxide.
  • copper salts include, but are not limited to, Copper(I) oxide, Copper(I) chloride, Copper(I) iodide, Copper(I) cyanide, Copper(I) thiocyanate, Copper(I) sulfate, Copper(I) sulfide, Copper(I) acetylide, Copper(I) bromide, Copper(I) fluoride, Cu(ACN)4 tritiate, Copper(I) hydroxide, Copper(I) hydride, Copper(I) nitrate, Copper(I) phosphide, Copper(I) thiophene-2-carboxylate, Copper(I) t-butoxide, Copper(II) sulfate, Copper(II) chloride, Copper(II) hydroxide, Copper(II) nitrate, Copper(II) oxide, Copper(II) acetate, Copper(II) fluoride, Copper(II) bromide, Copper(II) carbonate, Copper
  • the copper salt is a copper (II) perchlorate (Cu(C104)2), a copper (II) CuSCh, a copper (II) Cu(OAc)2, a copper (II) CuCh, a copper (I) Cu(ACN)4 tritiate, a copper (I) CuBr, or a copper (I) CuCl.
  • compositions of the present disclosure also include one or more oxidants.
  • the oxidation of alcohols to their corresponding carbonyl compounds is a fundamental transformation in organic chemistry.
  • an alcohol moiety of a 5 -hydroxymethyl cytosine base is converted into its respective carbonyl, thereby providing a 5-formyl cytosine base.
  • the oxidant used to achieve this transformation is an amine oxide, also known as amine N-oxides or N-oxides.
  • the N-oxide is 2, 2,6,6- Tetramethylpiperidinyloxy or 2,2,6,6-tetramethylpiperidine-l-oxyl (TEMPO).
  • the N-oxide is 9-Azabicyclo[3.3.1]nonane N-Oxyl (ABNO).
  • the N-oxide is 2-Azaadamantane N-Oxyl (AZADO) or a derivative or analog thereof (e.g., 1-Me-AZADO, 2-azaadamantane N-oxyl- AZ ADO, 1,3-dimethyl-AZADO, 1,3-dimethyl-AZADO, 9- azabicyclo[3.3.1]nonane-N-oxyl, and 9-azanoradamantane N-oxyl-AZADO).
  • AZADO 2-Azaadamantane N-Oxyl
  • 1-Me-AZADO 2-azaadamantane N-oxyl- AZ ADO
  • 1,3-dimethyl-AZADO 1,3-dimethyl-AZADO
  • 9-azanoradamantane N-oxyl-AZADO 9-azanoradamantane N-oxyl-AZADO
  • compositions of the present disclosure also include a compound (referred to herein as an "adduct forming reagent" having Formula (I): (i),
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl.
  • R is cyano. In some embodiments, R is a methyl or ethyl. In yet other embodiments, R is a carboxylic ester.
  • compositions of the present disclosure utilize a chelator selected from one of a bipyridine or a phenanthroline.
  • Suitable bipyridines include 2,2'-bipyridine and derivatives thereof.
  • suitable bipyridines include one substituent or two substituents.
  • suitable bipyridines include two or more substituents.
  • disubstituted bipyridines may be symmetrical or unsymmetrical and have Formula (II A):
  • Ri, R2, R3, and R4 are independently H, methyl, -CHR 7 , - OH, -OMe, -OCH2R 7 , -NH2, -NHR 7 , -NR 7 R 7 , and -SO3, where each R 7 is independently a C1-C4 alkyl group.
  • the chelator is a phenanthroline having Formula (IIB):
  • Ri, R2, R3, R4, Rs, and Re are independently H, methyl, - CHR 7 , -OH, -OMe, -OCH2R 7 , -NH2, -NHR 7 , -NR 7 R 7 , and -SO3, where each R 7 is independently a C1-C4 alkyl group.
  • Non-limiting examples of derivatives of 2,2'-bipyridine include, but are not limited to, 4,4'-dimethyl-2,2'-bipyridine, 5,5'-dimethyl-2,2'-bipyridine 4,4'- diethyl-2,2'-bipyridine, 5,5'-diethyl-2,2'-bipyridine, 4,4'-dimethoxy-2,2'-bipyridine, 5,5'-dimethoxy-2,2'-bipyridine.
  • the phenanthroline is 1,10-Phenanthroline.
  • compositions of the present disclosure include one or more buffers.
  • suitable buffers include TRIS ((tri s(hydroxymethyl)aminom ethane, or
  • 2-amino-2-(hydroxymethyl)propane-l,3-diol 2-amino-2-(hydroxymethyl)propane-l,3-diol
  • HEPES ((4-(2 -hydroxy ethyl)- 1- piperazineethanesulfonic acid); MOPS (3-(N-morpholino)propanesulfonic acid); TAPS (([tris(hydroxymethyl)methylamino]propanesulfonic acid); TEST (2-[[l,3- dihydroxy -2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid); and phosphate.
  • Suitable bases include strong bases including, but not limited to, NaOH, LiOH, KOH, RbOH, CsOH, Ca(OH) 2 , Sr(OH) 2 , and Ba(OH) 2 .
  • the base is NaOH.
  • a first composition (referred to herein as a "5-fC adduct forming composition") of the present disclosure is adapted for preparing nucleic acid molecules including one or more adducts of 5-formyl cytosine (hereinafter referred to as “5-formyl cytosine adducts" or “5-fC adducts”) from nucleic acid molecules including one or more 5-formyl cytosine bases.
  • the 5-fC adduct forming composition includes one or more nucleic acid molecules each having one or more 5-formyl cytosine bases, a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an adduct forming reagent having Formula (I), wherein the copper salt, the chelator, and adduct forming reagent having Formula (I) may be selected from any of those enumerated herein.
  • the copper salt is complexed with the chelator.
  • the 5-fC adduct forming composition includes a solvent, such as acetonitrile.
  • the target nucleic acid molecules in the 5-fC adduct forming compositions are single stranded or double stranded and include one 5-formyl cytosine base, at least two 5-formyl cytosine bases, at least three 5-formyl cytosine bases, at least four 5-formyl cytosine bases, at least five 5-formyl cytosine bases, at least six 5-formyl cytosine bases, etc.
  • the 5-fC adduct forming composition has a pH ranging from between about 7 to about 12.5. In some embodiments, the 5-fC adduct forming composition has a pH ranging from between about 8 to about 12.0. In some embodiments, the 5-fC adduct forming composition has a pH of about 8. In some embodiments, the 5-fC adduct forming composition has a pH of about 8.5. In some embodiments, the 5-fC adduct forming composition has a pH of about 9. In some embodiments, the 5-fC adduct forming composition has a pH of about 9.5. In some embodiments, the 5-fC adduct forming composition has a pH of about 10.
  • the 5-fC adduct forming composition has a pH of about 10.5. In some embodiments, the 5-fC adduct forming composition has a pH of about 11. In some embodiments, the 5-fC adduct forming composition has a pH of about 11.5. In some embodiments, the 5-fC adduct forming composition has a pH of about 12. In some embodiments, the 5-fC adduct forming composition has a pH of about 12.5.
  • the 5-fC adduct forming composition comprises a strong base.
  • the strong base is selected from the group consisting of NaOH, KOH, and Li OH.
  • an amount of base is added such that the composition has a pH ranging from about 7 to about 12.5, such as from about 8 to about 12.5.
  • a suitable composition for converting one or more 5-fC bases to 5-formyl cytosine bases includes between about 2mM to about 20 mM of NaOH.
  • a suitable composition for converting one or more 5-fC bases to 5-fC adducts includes about 2 mM to about 10 mM NaOH.
  • the 5-fC adduct forming composition comprises a buffer.
  • the buffer is TRIS.
  • a suitable composition for converting one or more 5 -hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 0 mM to about 50 mM of TRIS.
  • a suitable composition for converting one or more 5- hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 1 mM to about 50 mM of TRIS.
  • a suitable composition for converting one or more 5 -hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 10 mM to about 50 mM of TRIS.
  • a suitable composition for converting one or more 5- hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 20 mM to about 50 mM of TRIS.
  • an amount of copper salt in the 5-fC adduct forming composition ranges from between about 0.5 mM to about 8 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition ranges from between about 0.5 mM to about 6 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition ranges from between about 0.5 mM to about 4 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition ranges from between about 1 mM to about 3 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition is about 1 mM.
  • an amount of copper salt in the 5-fC adduct forming composition is about 1.5 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition is about 1.75 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition is about 2 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition is about 2.25 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition is about 2.5 mM. In some embodiments, an amount of copper salt in the 5-fC adduct forming composition is about 3 mM.
  • an amount of chelator in the 5-fC adduct forming composition ranges from between about 1 mM to about 20 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition ranges from between about 1 mM to about 15 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition ranges from between about 1 mM to about 10 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition ranges from between about 2 mM to about 8 mM.
  • an amount of chelator in the 5-fC adduct forming composition ranges from between about 2 mM to about 6 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 1 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 2 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 2.5 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 3 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 3.5 mM.
  • an amount of chelator in the 5-fC adduct forming composition is about 4 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 4.5 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 5 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 5.5 mM. In some embodiments, an amount of chelator in the 5-fC adduct forming composition is about 6 mM.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition ranges from between about 1 :5 to about 1 : 1. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition ranges from between about 1 :4 to about 1 : 1. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition ranges from between about 1 :3 to about 1 : 1. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2.8.
  • a ratio of an amount of copper salt to an amount of chelator in the 5- fC adduct forming composition is about 1 :2.7. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2.6. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2.5. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2.4.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2.3. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2.2. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 :2. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 : 1.8.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 : 1.6. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 : 1.4. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC adduct forming composition is about 1 : 1.2. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the composition for converting is about 1 : 1.
  • the copper salt in the 5-fC adduct forming composition is selected from Cu(C104)2, Cu(OAc)2, CuSCh, Cu(ACN)4triflate; and the chelator is 2,2'-bipyridine or a derivative thereof.
  • the copper salt is selected from Cu(C104)2, Cu(OAc)2, CuSCh, Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt in the 5-fC adduct forming composition is selected from Cu(C104)2, Cu(OAc)2, CuSCh, Cu(ACN)4 tritiate; and the chelator is 2,2'- bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt in the 5-fC adduct forming composition is selected from Cu(C104)2, Cu(OAc)2, CuSO4, Cu(ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt in the 5-fC adduct forming composition is Cu(C104)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt in the 5-fC adduct forming composition is Cu(C104)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt in the 5-fC adduct forming composition is Cu(C104)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt in the 5-fC adduct forming composition is Cu(C104)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt in the 5-fC adduct forming composition is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine.
  • the copper salt in the 5-fC adduct forming composition is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt in the 5-fC adduct forming composition is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt in the 5-fC adduct forming composition is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt in the 5-fC adduct forming composition is Cu(OAc)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt in the 5-fC adduct forming composition is Cu(OAc)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt in the 5-fC adduct forming composition is Cu(OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt in the 5-fC adduct forming composition is Cu(OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • compositions for converting one or more 5-fC bases to one or more 5-fC adducts comprises an adduct forming reagent having Formula (I), (i),
  • R is an electron-withdrawing group selected from cyano, nitro, Ci-Ce alkyl, carboxylic ester, unsubstituted carboxamide, Ci-Ce alkyl mono-substituted carboxamide, Ci-Ce alkyl disubstituted carboxamide, a substituted carbonyl moiety, and a substituted sulfonyl moiety, wherein the substitution is selected from a Ci-Ce linear or branched alkyl group, a C4-C6 cycloalkyl group, phenyl, 5- or 6-membered heteroaryl, and benzannulated 5- or 6-membered heteroaryl.
  • an amount of adduct forming reagent having Formula (I) in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 50 mM to about 2500 mM. In some embodiments, an amount of adduct forming reagent having Formula (I) in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 50 mM to about 2000 mM. In some embodiments, an amount of adduct forming reagent having Formula (I) in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 50 mM to about 1000 mM.
  • an amount of adduct forming reagent having Formula (I) in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 50 mM to about 500 mM. In some embodiments, an amount of adduct forming reagent having Formula (I) in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 50 mM to about 200 mM. In other embodiments, an amount of adduct forming reagent having Formula (I) in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 75 mM to about 100 mM.
  • the adduct forming reagent in the compositions for converting one or more 5-fC bases to one or more 5-fC adducts is malononitrile (i.e., where R is cyano).
  • an amount of malononitrile in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 50 mM to about 200 mM. In other embodiments, an amount of malononitrile in the composition for converting one or more 5-fC bases to one or more 5-fC adducts ranges from about 75 mM to about 100 mM.
  • compositions for converting 5-fC bases to 5-fC adducts in single stranded or double stranded nucleic acids are set forth below: [0155] Compositions for Converting 5-hmC Bases to 5-fC Bases
  • a second composition of the present disclosure is adapted for preparing nucleic acid molecules (such as single stranded and double stranded nucleic acid molecules) having one or more 5-formyl cytosine bases from nucleic acid molecules including one or more 5-hydroxymethyl cytosine bases (referred to herein as "5-fC forming compositions").
  • the 5-fC forming composition includes one or more nucleic acid molecules (such as single stranded and double stranded nucleic acid molecules) each having one or more 5-hydroxymethyl cytosine bases, a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide reagent, wherein the copper salt, the chelator, and the N-oxide reagent may be selected from any of those enumerated herein.
  • the N-oxide reagent is not TEMPO.
  • the N-oxide reagent is selected from ABNO, AZADO, and Me-AZADO.
  • the 5-fC forming composition includes a solvent, such as acetonitrile.
  • the target nucleic acid molecules in the 5-fC forming compositions are single stranded or double stranded and include one 5- hydroxymethyl cytosine base, at least two 5-hydroxymethyl cytosine bases, at least three 5-hydroxymethyl cytosine bases, at least four 5-hydroxymethyl cytosine bases, at least five 5-hydroxymethyl cytosine bases, at least six 5-hydroxymethyl cytosine bases, etc.
  • the 5-fC forming composition has a pH ranging from between about 7 to about 12.5. In some embodiments, the 5-fC forming composition has a pH ranging from between about 8 to about 12.0. In some embodiments, the 5-fC forming composition has a pH of about 8. In some embodiments, the 5-fC forming composition has a pH of about 8.5. In some embodiments, the 5-fC forming composition has a pH of about 9. In some embodiments, the 5-fC forming composition has a pH of about 9.5. In some embodiments, the 5-fC forming composition has a pH of about 10. In some embodiments, the 5-fC forming composition has a pH of about 10.5.
  • the 5-fC forming composition has a pH of about 11. In some embodiments, the 5-fC forming composition has a pH of about 11.5. In some embodiments, the 5-fC forming composition has a pH of about 12. In some embodiments, the 5-fC forming composition has a pH of about 12.5.
  • the 5-fC forming composition comprises a strong base.
  • the strong base is selected from the group consisting of NaOH, KOH, and Li OH.
  • an amount of base is added such that the composition has a pH ranging from about 7 to about 12, such as from about 8 to about 12.
  • a suitable composition for converting one or more 5 -hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 5mM to about 20 mM of NaOH.
  • a suitable composition for converting one or more 5 -hydroxymethyl cytosine bases to 5-formyl cytosine bases includes about 10 mM of NaOH.
  • the 5-fC forming composition comprises a buffer.
  • the buffer is TRIS.
  • a suitable composition for converting one or more 5 -hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 0 mM to about 50 mM of TRIS.
  • a suitable composition for converting one or more 5- hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 1 mM to about 50 mM of TRIS.
  • a suitable composition for converting one or more 5 -hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 5 mM to about 50 mM of TRIS.
  • a suitable composition for converting one or more 5- hydroxymethyl cytosine bases to 5-formyl cytosine bases includes between about 10 mM to about 50 mM of TRIS.
  • an amount of copper salt in the 5-fC forming composition ranges from between about 0.5 mM to about 8 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition ranges from between about 0.5 mM to about 6 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition ranges from between about 0.5 mM to about 4 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition ranges from between about 1 mM to about 3 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition is about 1 mM.
  • an amount of copper salt in the 5-fC forming composition is about 1.5 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition is about 1.75 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition is about 2 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition is about 2.25 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition is about 2.5 mM. In some embodiments, an amount of copper salt in the 5-fC forming composition is about 3 mM.
  • an amount of chelator in the 5-fC forming composition ranges from between about 1 mM to about 20 mM. In some embodiments, an amount of chelator in the 5-fC forming composition ranges from between about 1 mM to about 15 mM. In some embodiments, an amount of chelator in the 5-fC forming composition ranges from between about 1 mM to about 10 mM. In some embodiments, an amount of chelator in the 5-fC forming composition ranges from between about 2 mM to about 8 mM. In some embodiments, an amount of chelator in the 5-fC forming composition ranges from between about 2 mM to about 6 mM.
  • an amount of chelator in the 5-fC forming composition is about 1 mM. In some embodiments, an amount of chelator in the 5- fC forming composition is about 2 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 2.5 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 3 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 3.5 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 4 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 4.5 mM.
  • an amount of chelator in the 5-fC forming composition is about 5 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 5.5 mM. In some embodiments, an amount of chelator in the 5-fC forming composition is about 6 mM.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition ranges from between about 1 :5 to about 1 : 1. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition ranges from between about 1 :4 to about 1 : 1. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition ranges from between about 1 :3 to about 1 : 1. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2.8.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2.7. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2.6. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5- fC forming composition is about 1 :2.5. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2.4. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2.3.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2.2. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :2. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5- fC forming composition is about 1 : 1.8. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 : 1.6. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 :1.4.
  • a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 : 1.2. In some embodiments, a ratio of an amount of copper salt to an amount of chelator in the 5-fC forming composition is about 1 : 1.
  • the copper salt is selected from Cu(C104)2, CU(OAC)2, CuSCh, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof.
  • the copper salt is selected from Cu(C104)2, CU(OAC)2, CUSO4, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is selected from Cu(C104)2, CU(OAC)2, CUSO4, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is selected from Cu(C104)2, Cu(OAc)2, CuSCh, Cu(ACN)4 triflate; and the chelator is 2,2'- bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu(C104)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu(C104)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu(C104)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu(C104)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine.
  • the copper salt is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu(ACN)4 triflate; and the chelator is 2,2'- bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu(ACN)4 triflate; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu(OAc)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu(OAc)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu(OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu(OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition ranges from between about 1 : 1 to about 1 :0.1. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition ranges from between about 1 :0.5 to about 1 :0.1.
  • a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.5. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.4. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.3.
  • a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.2. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me- AZADO) in the 5-fC forming composition is about 1 :0.1.
  • the copper salt in the 5-fC forming composition is selected from Cu(C104)2, Cu(OAc)2, CuSO4, Cu(ACN)4triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof.
  • the copper salt in the 5-fC forming composition is selected from Cu(C104)2, CU(OAC)2, CUSO4, Cu(ACN)4triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.4.
  • the copper salt in the 5-fC forming composition is selected from Cu(C104)2, CU(OAC)2, CUSO4, Cu(ACN)4triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.3.
  • the copper salt in the 5-fC forming composition is selected from Cu(C104)2, CU(OAC)2, CUSO4, Cu(ACN)4triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.2.
  • the copper salt in the 5-fC forming composition is selected from Cu(C104)2, CU(OAC)2, CUSO4, Cu(ACN)4triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.1.
  • compositions for converting 5-hmC bases to 5-fC bases in single stranded or double stranded nucleic acids are set forth below:
  • the present disclosure is also directed to methods of preparing target nucleic acid molecules including one or more 5-formyl cytosine bases or adducts thereof.
  • the present disclosure provides a "one pot" synthetic method of forming adducts of the 5-formyl cytosine bases.
  • the methods of the present disclosure comprise converting one or more 5-fC bases within one or more nucleic acid molecules to one or more 5-fC adducts.
  • the conversion of the one or more 5-fC bases to the one or more 5-fC adducts takes place in the presence of a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, an adduct forming reagent (such as the adduct forming reagent having Formula (I), such as set forth in Scheme 1 below).
  • the product of the reaction i.e., the one or more 5-fC adducts
  • the product of the reaction may be used in one or more downstream processes, but not limited to, one or more amplification and/or one or more sequencing processes (such as to detect epigenetic changes in one or more target nucleic acid molecules).
  • the conversion of the one or more 5-fC based to their respective adduct takes place using any one of the 5-fC adduct forming compositions described herein including, but not limited to, any of those set forth in Composition Examples 1 - 3.
  • the method comprises contacting a sample comprising one or more nucleic acid molecules each having one or more 5-fC bases with any one of the 5-fC adduct forming compositions described herein, such as for a predetermined amount of time and at a predetermined temperature.
  • the sample is contacted with any one of the 5- fC adduct forming compositions described herein, wherein the 5-fC adduct forming composition has a pH ranging from between about 7 to about 12.5, such as a pH ranging from between about 8 to about 12.0.
  • the conversion is allowed to proceed at a temperature ranging from between about 20°C to about 35°C, such as between about 25°C to about 30°C. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 1 minute to about 120 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 1 minute to about 90 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 1 minute to about 60 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 1 minute to about 45 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 1 minute to about 30 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 1 minute to about 15 minutes.
  • the present disclosure provides methods of preparing one or more nucleic acid molecules each having one or more 5-fC adducts, wherein the method comprises (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5-formyl cytosine bases; and (b) reacting the obtained sample, for a predetermined amount of time and at a predetermined temperature, with a composition comprising a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an adduct forming.
  • the adduct forming reagent is any compound capable of forming an adduct of a 5-fC base incorporated within a nucleic acid molecule.
  • the adduct forming agent has Formula (I) as set forth herein.
  • the adduct forming agent is malononitrile.
  • the reaction occurs at a pH ranging from between about 7 to about 12.5, such as between about 8 to about 12.
  • the reaction is performed at room temperature.
  • the reaction is performed at a temperature ranging from about 20°C to about 35°C, such as between about 25°C to about 30°C.
  • the reaction is allowed to proceed for a time period ranging from about 1 minute to about 120 minutes.
  • the reaction is allowed to proceed for a time period ranging from about 1 minute to about 90 minutes.
  • the reaction is allowed to proceed for a time period ranging from about 1 minute to about 60 minutes.
  • the reaction is allowed to proceed for a time period ranging from about 1 minute to about 45 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 30 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 15 minutes.
  • the copper salt is selected from Cu(C104)2, CU(OAC)2, CuSCh, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof.
  • the copper salt is selected from Cu(C104)2, CU(OAC)2, CUSO4, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is selected from Cu(C104)2, CU(OAC)2, CuSCh, Cu(ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is selected from Cu (C1O4)2, CU(OAC)2, CUSO4, CU(ACN)4 tritiate; and the chelator is 2,2'- bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'-bipyridine.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'- bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the bipyridine is about 1 : 1.8.
  • the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the bipyridine is about 1 : 1.8.
  • the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the bipyridine is about 1 : 1.8.
  • an amount of adduct forming reagent ranges from about 50 mM to about 200 mM. In other embodiments, an amount of adduct forming reagent ranges from about 75 mM to about 100 mM. In some embodiments, an amount of the adduct forming reagent is about 100 mM. In other embodiments, an amount of the adduct forming reagent is about 125 mM. In yet other embodiments, an amount of the adduct forming reagent is about 150 mM.
  • the adduct forming reagent is malononitrile (i.e., where R is cyano).
  • an amount of malononitrile ranges from about 50 mM to about 200 mM. In other embodiments, an amount of malononitrile is about 100 mM. In other embodiments, an amount of malononitrile is about 125 mM. In other embodiments, an amount of malononitrile is about 150 mM. In other embodiments, an amount of malononitrile is about 175 mM. In other embodiments, an amount of malononitrile is about 200 mM.
  • reaction is complete within about 45 minutes to about 60 minutes when using malononitrile in an amount ranging from between about 125 mM to about 150 mM and using a copper salt in an amount of about 2 mM. It is also believed that the reaction is complete within 70 minutes when using malononitrile in an amount of about 100 mM.
  • the copper salt is Cu (CICh)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile.
  • the copper salt is Cu (CICh)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (CICh)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (C1O4)2; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1: 1.8.
  • the copper salt is Cu (OAc)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile.
  • the copper salt is Cu (OAc)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (OAc)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (OAc)?; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1: 1.8.
  • the copper salt is Cu (ACN)4 triflate; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile.
  • the copper salt is Cu (ACN)4 triflate; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (ACN)4 triflate; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (ACN)4 triflate; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1: 1.8.
  • both single stranded and double stranded nucleic acid molecules including one or more 5-fC bases are modified with high efficiencies in less than about 1 hour at about 25°C in the presence of about 2mM of a copper salt, about 3 mM to about 4 mM of a bipyridine, and 150 mM of an adduct forming reagent (e.g., malononitrile). It is believed that the reaction can be carried out with highly basic and denatured samples (e.g., about 10 to about 20 mM of NaOH) or with slightly alkaline samples including buffers such as about 10 mM TRIS at a pH of about 8 (see Example 2, FIG. 1).
  • highly basic and denatured samples e.g., about 10 to about 20 mM of NaOH
  • slightly alkaline samples including buffers such as about 10 mM TRIS at a pH of about 8 (see Example 2, FIG. 1).
  • the methods of the present disclosure comprise converting one or more 5-hmC bases within one or more nucleic acid molecules to one or more 5-fC bases.
  • the conversion of the one or more 5-hmC bases to the one or more 5-fC bases takes place in the presence of a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an oxidant (such as an N-oxide, preferably ABNO, AZADO, and Me-AZADO), such as set forth in Scheme 2 below.
  • the conversion of the one or more 5-hmC bases to the one or more 5-fC bases is free from TEMPO.
  • the conversion of the one or more 5-hmC to one or more 5-fC bases takes place using any one of the 5-fC forming compositions described herein including, but not limited to, any of those set forth in Composition Examples 4 - 6.
  • the method comprises contacting a sample comprising one or more nucleic acid molecules each having one or more 5-hmC bases with any one of the 5-fC forming compositions described herein (such as for a predetermined about of time and at a predetermined temperature).
  • the sample is contacted with any one of the 5- fC forming compositions described herein, wherein the 5-fC forming composition has a pH ranging from between about 7 to about 12.5, such as a pH ranging from between about 8 to about 12.5.
  • the conversion is allowed to proceed at a temperature ranging from about 20°C to about 35°C, such as between about 25°C to about 30°C.
  • the conversion is allowed to proceed for a time period ranging from about 10 minutes to about 200 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 10 minutes to about 120 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 10 minutes to about 90 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 10 minutes to about 60 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 10 minutes to about 45 minutes. In some embodiments, the conversion is allowed to proceed for a time period ranging from about 10 minutes to about 30 minutes.
  • the product of the reaction (the one or more formed 5-fC bases) may be used as a starting material for a further downstream reaction, such as in a one-pot synthesis.
  • the present disclosure provides methods of preparing one or more nucleic acid molecules each having one or more 5-fC bases, wherein the method comprises (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5 -hydroxymethyl cytosine bases; and (b) reacting the obtained sample, for a predetermined amount of time and at a predetermined temperature, with a composition comprising a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide (e.g., preferably ABNO, AZADO, and Me-AZADO).
  • the composition including the N-oxide is free from TEMPO.
  • the reaction occurs at a pH ranging from between about 7 to about 12.5, such as between about 8 to about 12.0.
  • the reaction is performed at room temperature. In other embodiments, the reaction is performed at a temperature ranging from about 20°C to about 35°C, such as between about 25°C to about 30°C. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 120 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 90 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 60 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 45 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 30 minutes. In some embodiments, the reaction is allowed to proceed for a time period ranging from about 1 minute to about 15 minutes.
  • the copper salt is selected from Cu (CICh CU(OAC)2, CuSCh, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof.
  • the copper salt is selected from Cu (004)2, CU(OAC)2, CUSO4, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is selected from Cu (004)2, CU(OAC)2, CUSO4, CU(ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is selected from Cu (004)2, CU(OAC)2, 1SO4, Cu(ACN)4 triflate; and the chelator is 2,2'- bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (ACN)4 triflate; and the chelator is 2,2'-bipyridine.
  • the copper salt is Cu (ACN)4 triflate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (ACN)4 triflate; and the chelator is 2,2'- bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (ACN)4 triflate; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu (OAc)?; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine.
  • the copper salt is Cu (CICh)?; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (CICh)?; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (CICh)?; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition ranges from between about 1 :0.5 to about 1 :0.1. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.5. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.4.
  • a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.3. In some embodiments, a ratio of an amount of copper salt to an amount of N- oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.2. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide (e.g., ABNO, AZADO, and Me-AZADO) in the 5-fC forming composition is about 1 :0.1.
  • the copper salt in the 5-fC forming composition is selected from Cu (C1O4)2, Cu(OAc)2, CuSO4, Cu(ACN)4triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof.
  • the copper salt in the 5-fC forming composition is selected from Cu (004)2, CU(OAC)2, CUSO4, CU(ACN)4 triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.4.
  • the copper salt in the 5-fC forming composition is selected from Cu (004)2, CU(OAC)2, Q1SO4, CU(ACN)4 tritiate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.3.
  • the copper salt in the 5-fC forming composition is selected from Cu (C1O4)2, CU(OAC)2, CUSO4, CU(ACN)4 tritiate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.2.
  • the copper salt in the 5-fC forming composition is selected from Cu (C1O4)2, CU(OAC)2, CUSO4, CU(ACN)4 tritiate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof, and wherein a ratio of an amount of copper salt to an amount of N-oxide in the composition is about 1 :0.1.
  • the product of the reaction i.e., one or more target nucleic acid molecules each having one or more 5-fC bases
  • the product of the reaction is used as a starting material for a downstream reaction without first purifying the product.
  • the product of the reaction i.e., one or more target nucleic acid molecules each having one or more 5-fC bases
  • the methods of the present disclosure comprise a "one pot" method of converting one or more 5-hmC bases of one or more nucleic acid molecules to one or more 5-fC adducts. It is believed that the "one pot" synthesis allows for tandem oxidation from a 5-hmC base to a 5-fC adduct, through a 5-fC intermediate in less than about three hours, such as less than about two hours. This, it is believed, is highly valuable, particularly for reducing sample preparation time for nucleic acid methylation sequencing reactions.
  • the product of the reaction i.e., the one or more 5-fC adducts
  • the product of the reaction may be used in one or more downstream processing steps including, but not limited to, one or more amplification and/or one or more sequencing processes (such as to detect epigenetic changes in one or more target nucleic acid molecules).
  • the "one pot" conversion of the one or more 5-hmC bases to the one or more 5-fC adducts takes place in a two-step reaction.
  • the one or more 5-hmC bases are reacted in the presence of a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an oxidant (such as an N-oxide) to provide a reaction mixture including one or more nucleic acid molecules having one or more 5-fC bases.
  • an adduct forming reagent (such as an adduct forming reagent having Formula (I)) is then introduced to the mixture including the one or more nucleic acid molecules including the one or more 5-fC bases to provide one or more nucleic acid molecules including one or more 5-fC adducts.
  • the second step takes place without first purifying the reaction mixture produced following the first step.
  • the two-step process may produce one or more target nucleic acid molecules including one or more 5-fC adducts in a time period of less than about 3 hours, such about 2 hours, or such as less than about 2 hours (e.g., about 90 minutes or less, about 60 minutes or less, etc.).
  • the "one pot" synthesis follows that of Scheme 3 (where the group R is that of Formula (I) herein), below.
  • the "one pot" synthesis first comprises contacting a sample including one or more nucleic acid molecules having one or more 5-hmC bases with a 5-fC forming composition, including any of the 5-fC forming compositions disclosed herein, to provide a reaction mixture including one or more nucleic acid molecules having one or more 5-fC bases.
  • the first step is allowed to proceed for about 90 minutes, such as about 60 minutes, such as about 30 minutes, depending, of course, on reaction conditions and the concentrations of reagents utilized (such as noted herein).
  • the resulting reaction mixture is then contacted with a 5-fC adducing forming composition, including any of the 5-fC adduct forming compositions disclosed herein, to provide one or more nucleic acid molecules including one or more 5-fC adducts.
  • the second step is allowed to proceed for about 90 minutes, such as about 60 minutes, such as about 30 minutes, depending, of course, on reaction conditions and the concentrations of reagents utilized (such as noted herein).
  • the reaction mixture is not purified prior to the second step.
  • the present disclosure provides a method of synthesizing one or more nucleic acid molecules each comprising one or more adducts of 5-formyl cytosine, the method comprising: (a) obtaining a sample comprising one or more nucleic acid molecules each having one or more 5- hydroxymethyl cytosine bases; (b) contacting the obtained sample with a first composition at a first temperature and for a first time period, wherein the first composition comprises a copper salt, a chelator selected from one of a bipyridine or a phenanthroline, and an N-oxide reagent (e.g., TEMPO, ABNO, AZ ADO, and Me- AZADO) to the sample to provide a mixture comprising one or more nucleic acid molecules each having one or more 5-formyl cytosine bases; and (c) contacting the resulting mixture with a second composition at a second temperature for a second time period, wherein the second composition includes an adduct
  • the adduct forming reagent is any compound capable of forming an adduct of a 5-fC base incorporated within a nucleic acid molecule.
  • the adduct forming agent has Formula (I) as set forth herein.
  • the adduct forming agent is malononitrile.
  • the first predetermined time period ranges from about 10 minutes to about 48 hours (if using the N-oxide TEMPO). In some embodiments, the first predetermined time period ranges from about 10 minutes to about 24 hours (if using the N-oxide TEMPO). In other embodiments, the first predetermined time period ranges from about 10 minutes to about 4 hours, such as about 10 minutes to about 3 hours, such as about 10 minutes to about 2 hours, such as about 10 minutes to about 1 hour, if using an N-oxide reagent selected from ABNO, AZADO, and Me-AZADO.
  • the second predetermined time period ranges from between about 1 minute to about 120 minutes, such as from about 5 minutes to about 90 minutes, such as from about 5 minutes to about 60, such as about 50 minutes, such as about 40 minutes, such as about 30 minutes.
  • the first and second predetermined temperatures independently range from between about 20 °C to about 35 °C, such as between about 25 °C to about 30°C.
  • the copper salt is selected from Cu (ClCh)?, CU(OAC)2, CuSCh, CU(ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof.
  • the copper salt is selected from Cu (004)2, CU(OAC)2, CUSO4, CU(ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is selected from Cu (004)2, CU(OAC)2, CUSO4, CU(ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is selected from Cu (004)2, CU(OAC)2, O1SO4, Cu(ACN)4 tritiate; and the chelator is 2,2'- bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'-bipyridine.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'- bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu (ACN)4 tritiate; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu (OAc)2; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine. In other embodiments, the copper salt is Cu (004)2; and the chelator is 2,2'-bipyridine or a derivative thereof; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2. In other embodiments, the copper salt is Cu (CICh)?; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2. In other embodiments, the copper salt is Cu (CICh)?; and the chelator is 2,2'-bipyridine; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 : 1.8.
  • a ratio of an amount of copper salt to an amount of N-oxide reagent ranges from between about 1 :0.5 to about 1 :0.1. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide reagent (e.g., TEMPO, ABNO, AZADO, and Me-AZADO) is about 1 :0.5. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide reagent (e.g., TEMPO, ABNO, AZADO, and Me-AZADO) is about 1 :0.4.
  • N-oxide reagent e.g., TEMPO, ABNO, AZADO, and Me-AZADO
  • a ratio of an amount of copper salt to an amount of N-oxide reagent is about 1 :0.3. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide reagent (e.g., TEMPO, ABNO, AZADO, and Me-AZADO) is about 1 :0.2. In some embodiments, a ratio of an amount of copper salt to an amount of N-oxide reagent (e.g., TEMPO, ABNO, AZADO, and Me-AZADO) is about 1 :0.1.
  • the copper salt in the 5-fC forming composition is selected from Cu(C104)2, Cu(OAc)2, CuSO4, Cu(ACN)4 triflate; and the N-oxide reagent is ABNO or AZADO or a derivative or analog thereof.
  • an amount of adduct forming reagent ranges from about 50 mM to about 200 mM. In other embodiments, an amount of adduct forming reagent ranges from about 75 mM to about 100 mM. In some embodiments, an amount of the adduct forming reagent is about 100 mM. In other embodiments, an amount of the adduct forming reagent is about 125 mM. In yet other embodiments, an amount of the adduct forming reagent is about 150 mM.
  • the adduct forming reagent is malononitrile (i.e., where R is cyano).
  • an amount of malononitrile ranges from about 50 mM to about 200 mM. In other embodiments, an amount of malononitrile is about 100 mM. In other embodiments, an amount of malononitrile is about 125 mM. In other embodiments, an amount of malononitrile is about 150 mM. In other embodiments, an amount of malononitrile is about 175 mM. In other embodiments, an amount of malononitrile is about 200 mM.
  • reaction is complete within about 45 minutes to about 60 minutes when using malononitrile in an amount ranging from between about 125 mM to about 150 mM. It is also believed that the reaction is complete within 70 minutes when using malononitrile in an amount of about 100 mM.
  • the copper salt is Cu(C104)2; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile.
  • the copper salt is Cu(C104)2; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.2.
  • the copper salt is Cu(C104)2; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1 :2.
  • the copper salt is Cu(C104)2; the chelator is 2,2'-bipyridine; and the adduct forming reagent is malononitrile; and wherein a ratio of an amount of the copper salt to an amount of the chelator is about 1: 1.8.
  • the present disclosure also provides for methods of amplifying and/or sequencing nucleic acid sequences including at least one modified cysteine base.
  • the present disclosure provides methods of detecting epigenetic modification in nucleic acids.
  • the method comprises obtaining one or more target nucleic acid molecules including one or more 5-hmC bases or one or more 5-fC bases and converting the one or more 5-hmC bases or the one or more 5-fC bases to one or more 5-fC adducts. Methods of converting the one or more 5-hmC bases or the one or more 5-fC bases to one or more 5-fC adducts are described herein.
  • the 5-fC adducts are 5-fC malononitrile adducts.
  • the sample comprising the one or more nucleic acid molecules having the one or more 5-fC adducts
  • the sample is contacted with a polymerase to provide one or more amplified nucleic acid molecules.
  • the polymerase is believed to read the 5-fC adduct as a thymine during amplification.
  • the one or more amplified nucleic acid molecules have a thymine base at a position corresponding to the position of the 5-fC adduct in each of the one or more nucleic acid molecules having the one or more adducts of 5- formyl cytosine.
  • the polymerase can copy a strand comprising a 5-fC adduct by recognizing the adduct as T (i.e., incorporating an A opposite the adduct).
  • Polymerases able to accommodate the 5-fC adduct described herein include DNA polymerases known to accommodate uracil (U) in a DNA strand.
  • polymerase may be a naturally-occurring or an engineered polymerase.
  • Non-limiting examples of polymerases include prokaryotic DNA polymerases (e.g., Pol I, Pol II, Pol III, Pol IV, and Pol V), eukaryotic DNA polymerase, archaeal DNA polymerase, telomerase, reverse transcriptase, and RNA polymerase.
  • Reverse transcriptase is an RNA-dependent DNA polymerase which synthesizes DNA from an RNA template.
  • the reverse transcriptase family contains both DNA polymerase functionality and RNase H functionality, which degrades RNA base-paired to DNA.
  • RNA polymerase is an enzyme that synthesizes RNA using DNA as a template during the process of gene transcription. RNA polymerase polymerizes ribonucleotides at the 3' end of an RNA transcript.
  • suitable polymerases may be derived from: archaea (e.g., Thermococcus litoralis (Vent, GenBank: AAA72101), Pyrococcus furiosus (Pfu, GenBank: DI 2983, BAA02362), Pyrococcus woesii, Pyrococcus GB- D (Deep Vent, GenBank: AAA67131), Thermococcus kodakaraensis KODI (KOD, GenBank: BD175553, BAA06142; Thermococcus sp.
  • archaea e.g., Thermococcus litoralis (Vent, GenBank: AAA72101), Pyrococcus furiosus (Pfu, GenBank: DI 2983, BAA02362), Pyrococcus woesii, Pyrococcus GB- D (Deep Vent, GenBank: AAA67131), Thermococcus kodakaraensis KOD
  • strain KOD (Pfx, GenBank: AAE68738)), Thermococcus gorgonarius (Tgo, Pdb: 4699806), Sulfolobus solataricus (GenBank: NC002754, P26811), Aeropyrum pernix (GenBank: BAA81109), Archaeglobus fulgidus (GenBank: 029753), Pyrobaculum aerophilum (GenBank: AAL63952), Pyrodictium occultum (GenBank: BAA07579, BAA07580), Thermococcus 9 degree Nm (GenBank: AAA88769, Q56366), Thermococcus fumicolans (GenBank: CAA93738, P74918), Thermococcus hydrothermalis (GenBank: CAC 18555), Thermococcus sp.
  • GE8 (GenBank: CAC12850), Thermococcus sp. JDF-3 (GenBank: AX135456; WO0132887), Thermococcus sp. TY (GenBank: CAA73475), Pyrococcus abyssi (GenBank: P77916), Pyrococcus glycovorans (GenBank: CAC12849), Pyrococcus horikoshii (GenBank: NP 143776), Pyrococcus sp. GE23 (GenBank: CAA90887), Pyrococcus sp.
  • the method of amplifying and/or sequencing further comprises ligating one or more adapters to the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine prior to contacting the one or more nucleic acid molecules having the one or more adducts of 5-formyl cytosine with the polymerase.
  • Adaptors of various shapes and functions are known in the art (see e.g., PCT/EP2019/05515 filed on February 28, 2019, US8822150 and US8455193, the disclosures of which are hereby incorporated by reference herein in their entireties).
  • the function of an adaptor is to introduce desired elements into a nucleic acid.
  • adaptor-borne elements include at least one of nucleic acid barcode, multiplex identifier, a unique molecular identifier, primer binding site, or a ligation-enabling site.
  • barcode refers to a nucleic acid sequence that can be detected and identified.
  • the barcodes comprise between about 5 and about 20 nucleotides, such that in a sample, the nucleic acids incorporating the barcodes can be distinguished or grouped according to the barcodes.
  • the barcodes comprise between about 5 and about 15 nucleotides.
  • the barcodes comprise between about 5 and about 10 nucleotides.
  • the barcodes comprise between about 10 and about 15 nucleotides.
  • the barcodes comprise about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15 nucleotides.
  • the barcode would have the Formula:
  • N includes (in the aggregate) about 25% adenosine; about 25% guanine; about 25% cytosine; and about 25% thymine; and W includes (in the aggregate) about 50% adenosine and about 50% thymine.
  • the term "multiplex identifier" or "MID" refers to a barcode that identifies a source of a target nucleic acid (e.g., a sample from which the nucleic acid is derived). In some embodiments, all or substantially all the target nucleic acids from the same sample will share the same MID. In some embodiments, nucleic acids from different sources or samples can be mixed and sequenced simultaneously. In some embodiments, by using the MIDs the sequence reads (obtained during a sequencing step, such as described herein) can be assigned to individual samples from which the target nucleic acids originated.
  • the term "unique molecular identifier" or "UID” refers to a barcode that identifies a nucleic acid to which it is attached.
  • UID unique molecular identifier
  • all or substantially all the target nucleic acids from the same sample will have different UIDs.
  • all or substantially all the progeny (e.g., amplicons) derived from the same original target nucleic acid will share the same UID.
  • the sequencing step involves sequence alignment.
  • aligning is used to determine a consensus sequence from a plurality of sequences, e.g., a plurality having the same unique molecular ID (UID).
  • the molecular ID is a barcode that can be added to each molecule prior to sequencing or if an amplification step is included, prior to the amplification step.
  • a UID is present in the 5'-portion of the RT primer.
  • a UID can be present in the 5'-end of the last barcode subunit to be added to the compound barcode.
  • a UID is present in an adaptor and is added to one or both ends of the target nucleic acid by ligation.
  • a consensus sequence is determined from a plurality of sequences all having an identical UID.
  • the sequences having an identical UID are presumed to derive from the same original molecule through amplification.
  • UID is used to eliminate artifacts, i.e., variations existing in the progeny of a single molecule (characterized by a particular UID). Such artifacts resulting from PCR errors or sequencing errors can be eliminated using UIDs.
  • the number of each sequence in the sample can be quantified by quantifying relative numbers of sequences with each UID among the population having the same MID.
  • each UID represents a single molecule in the original sample and counting different UIDs associated with each sequence variant can determine the fraction of each sequence variant in the original sample, where all molecules share the same MID.
  • a person skilled in the art will be able to determine the number of sequence reads necessary to determine a consensus sequence.
  • the relevant number is reads per UID ("sequence depth") necessary for an accurate quantitative result.
  • the desired depth is 5 - 50 reads per UID.
  • the present disclosure provides a kit including components for detecting epigenetic changes and/or performing amplification.
  • the kit includes components for detecting cytosine methylation in nucleic acids by detecting 5-fC.
  • a kit comprises (i) a copper salt; (ii) a chelator selected from one of a bipyridine or a phenanthroline; (iii) an adduct forming reagent; (iv) a polymerase; and (v) optionally one or more PCR reagents.
  • the copper salt and the chelator are included in a single container and mixed in a predetermined ratio.
  • the pre-determined ratio is about 1 :2.5 (chelator : copper).
  • the pre-determined ratio is about 1 :2.25 (chelator : copper).
  • the pre-determined ratio is about 1 :2 (chelator : copper).
  • the pre-determined ratio is about 1 : 1.75 (chelator : copper). In some embodiments, the pre-determined ratio is about 1 : 1.5 (chelator : copper). In some embodiments, the adduct forming reagent is malononitrile.
  • the polymerase is selected from those described herein.
  • a polymerase is a Taq or Taq-derived polymerase (e.g., KAPA 2G polymerase from KAPA BIOSYSTEMS).
  • KAPA 2G polymerase from KAPA BIOSYSTEMS
  • B-family DNA polymerase e.g., KAPA HIFI polymerase from KAPA BIOSYSTEMS.
  • the PCR reagents comprise nucleotides.
  • the PCR reagents include deoxynucleoside triphosphates (dNTPs), all the four naturally occurring deoxynucleoside triphosphates (dNTPs).
  • the PCR reagents include deoxyribonucleoside triphosphate molecules, including all dATP, dCTP, dGTP, dTTP.
  • the PCR reagents also include compounds useful in assisting the activity of the nucleic acid polymerase.
  • the PCR reagent include a divalent cation, e.g., magnesium ions.
  • the magnesium ions are provided in the form of magnesium chloride, magnesium acetate, or magnesium sulfate.
  • the PCR reagents further include a buffer or buffer solution.
  • each of the PCR reagents are provided alone. In other embodiments, each of the PCR reagents are provided in admixture.
  • the kit includes one or more adapter molecules and/or a ligase. [0246] In some embodiments, the kit further includes one or more bases, buffers, and/or oxidants.
  • a kit in some embodiments, includes a chelator and a copper salt pre-mixed in a first container and an N-oxide reagent (e.g., TEMPO, ABNO, AZADO, and Me-AZADO) in a second container.
  • an N-oxide reagent e.g., TEMPO, ABNO, AZADO, and Me-AZADO
  • the kit further includes one or more buffers and/or bases.
  • a kit in some embodiments, includes a chelator and a copper salt pre-mixed in a first container and an adduct forming reagent (such as any of those of Formula (I) in a second container.
  • the kit further includes one or more buffers and/or bases.
  • a solution of the complex was prepared as follows:25 pL of about 100 mM CU(OAC)2 in water or about 100 mM Cu(ACN)4 triflate in acetonitrile was added to about 50 pL of about 100 mM 2,2'-bipyridine (Bpy) in acetonitrile followed with about 15 pL water and about 10 pL of about 100 mM aq NaOH (about 25 mM Cu / about 50 mM Bpy). It was vortexed for about 30 seconds.
  • FIG. 1 shows the mass of the unreacted oligo.
  • FIG. 1 shows the reaction in 10 mM tris pH 8.
  • FIG. 1 shows the reaction in 10 mM NaOH.
  • FIG. 1 shows the reaction in presence of about 2 mM Cu(OAc)2, about 4 mM Bpy and about 10 mM NaOH,
  • FIG. 1 shows the reaction in presence of 2 mM Cu(OAc)2, about 4mM Bpy and about 10 mM tris pH about 8.
  • the reactions were only partially completed when no Cu/Bpy complex was used, but they were complete within 1 hour when the complex was used.
  • the reactions contained 20 mM aq NaOH, 15-20% acetonitrile, and had a total volume of 50 pL.
  • the reactions were purified using Zymo DNA clean, and the obtained product was analyzed by LC-MS to compare the progress of the reaction.
  • Molecular weights of starting fC oligo, complementary oligo, and Mal-fC oligo were 9978, 9866, and 10026 Da, respectively.
  • FIG. 2 shows the reaction with about 2mM Cu(C104)2.
  • FIG. 2 shows the reaction with about 3 mM Bpy.
  • FIG. 2 shows the reaction with about 2 mM Cu(C104)2 and about 3 mM Bpy.
  • FIG. 2 shows the reaction with about 2 mM Cu(C104)2 and about 3 mM Bpy, 2 mM TEMPO.
  • FIG. 2 only the conditions that at least had both Cu(II) salt and Bpy went to completion in about 1 hour, indicating that the Cu/Bpy complex was more effective in catalyzing the malononitrile adduct formation than individual components.
  • TCACGTCCAGATCAATCGACTATGAGCAGTAC were subjected to treatment with about 150 mM malononitrile in presence of about 2 to about 5 mM Cu(ACN)4 triflate and about 1.25 eq of Bpy at about 25°C.
  • the reactions contained about 10 mM aq NaOH, about 15 to about 20% acetonitrile, and had a total volume of about 50 pL.
  • the reaction time decreased as the concentration of the copper complex increased.
  • the reactions were purified using Zymo DNA clean, and the obtained product was analyzed by LC-MS to compare the progress of the reaction.
  • the molecular weights of starting fC oligo, complementary oligo, and Mal-fC oligo were 9978, 9866, and 10026 Da, respectively.
  • FIG. 3 shows the adduct formation completed within 45 minutes with 2mM Cu(ACN)4 triflate and 2.5 mM Bpy.
  • FIG. 3 shows the reaction completed within 30 minutes with 3 mM Cu(ACN)4 triflate and 3.75 mM Bpy.
  • FIG. 3 shows the reaction completed within 22 minutes with 4mM CU(ACN)4 triflate and 5 mM Bpy.
  • FIG. 3 (trace S4) shows the reaction completed within about 15 minutes with 6mM Cu(ACN)4 triflate and about 7.5 mM Bpy. As seen in FIG.
  • the time needed for the competition of the adduct formation is inversely correlated with the concentration of copper/Bpy complex.
  • the rate of the adduct formation is proportional to the concentration of copper complex.
  • Higher concentrations of copper however reduced the recovery of the DNA oligos due to some precipitate formation during the reaction. It was decided that about 2 mM copper was enough to allow the adduct formation to be completed within about 1 hour without causing a significant loss of DNA oligo during the reaction.
  • TCACGTCCAGATCAATCGACTATGAGCAGTAC were subjected to treatment with 75-150 mM malononitrile in presence of about 2 to about 4 mM Cu(ACN)4 triflate/1.25 eq of Bpy at about 25°C.
  • the reactions contained about 10 mM aq NaOH, about 15 to about 20% acetonitrile, and had a total volume of about 50 pL.
  • the ds-DNA oligo was treated with the usual about 150 mM of malononitrile with about 2 mM Cu(I) as shown in FIG. 4 (trace SI).
  • the oligo was treated with half the amount of malononitrile (about 75 mM) but in presence of twice as much concentration (about 4 mM) of Cu(I) as shown in FIG. 4 (trace S2). Both reactions took about 45 minutes to complete.
  • Molecular weights of starting fC oligo, complementary oligo, and Mal-fC oligo were 9978, 9866, and 10026 Da, respectively.
  • Example 6 Conversion Rate of Oligonucleotide Containing 1 fC Base Treated with Standard 150 mM malononitrile in TRIS versus Cu / 2,2’- Bipyridine complex Added 100 mM Malononitrile Studied by sequencing
  • adapter ligated 5-fC modified oligo (SEQ ID NO: 1 5'-Phos- CACGTCCAGATCAAT(fC)GACTATGAGCAGTACA) was treated with either about 150 mM malononitrile in about 10 mM tris, pH about 8.0 at about 37°C, for about 20 hours or in the accelerated condition: lOmM NaOH, about 2 mM Cu(C104)2 and about 4 mM Bpy, about 100 mM malononitrile, about 15% acetonitrile at room temperature for about 70 mins.
  • the products were purified, and PCR amplified with KAPA 2G for either about 30s or about 2 min extension. The samples were subsequently sequenced.
  • the results as shown in FIG. 5 demonstrates the conversion rates for the accelerated condition were comparable to the standard overnight condition.
  • This example describes a general procedure for performing a tandem oxidation / Malononitrile adduct formation on hmC oligos using copper/2,2'- bipyridine (Bpy) complex.
  • a solution of the complex was prepared as follows:25 pL 100 mM Cu(C104)2 in water was added to about 50 pL of about 100 mM Bpy in acetonitrile followed by about 25 pL water (about 25 mM Cu / about 50 mM Bpy). This was vortexed for about 30 seconds.
  • the reaction was vortexed for about 5 seconds and then incubated at about 25°C without shaking for about 50 to about 60 minutes.
  • the reaction was then immediately treated with about 7.5 pL of about 1 M malononitrile in acetonitrile. This was shaken at about 25°C for about 60 minutes and then purified using Zymo DNA clean filters according to the corresponding instructions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Sont divulguées dans la description des compositions destinées à être utilisées dans la préparation de molécules d'acide nucléique cibles comprenant une ou plusieurs bases 5-formyl cytosine ou un ou plusieurs adduits de 5-formyl cytosine. Sont également divulgués dans la description des procédés de synthèse efficace de molécules d'acide nucléique comprenant une ou plusieurs bases 5-formyl cytosine à partir de molécules d'acide nucléique cibles qui comprennent une ou plusieurs bases 5-hydroxyméthyl cytosine. La présente divulgation propose également des procédés de détection de modifications épigénétiques dans une molécule d'acide nucléique cible, telles que les modifications épigénétiques caractérisées par la méthylation de la cytosine à la position 5 (p. ex., 5-méthyl cytosine, 5-hydroxyméthyl cytosine).
PCT/EP2024/066001 2023-06-14 2024-06-11 Marquage accéléré de 5-formyl cytosine et utilisation dans le séquençage de méthylation d'acide nucléique Pending WO2024256358A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472951P 2023-06-14 2023-06-14
US63/472,951 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024256358A2 true WO2024256358A2 (fr) 2024-12-19
WO2024256358A3 WO2024256358A3 (fr) 2025-01-16

Family

ID=91539763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/066001 Pending WO2024256358A2 (fr) 2023-06-14 2024-06-11 Marquage accéléré de 5-formyl cytosine et utilisation dans le séquençage de méthylation d'acide nucléique

Country Status (1)

Country Link
WO (1) WO2024256358A2 (fr)

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000159A (en) 1974-06-28 1976-12-28 Phillips Petroleum Company Preparation of n,n-disubstituted thioamides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5176995A (en) 1985-03-28 1993-01-05 Hoffmann-La Roche Inc. Detection of viruses by amplification and hybridization
WO2001032887A1 (fr) 1999-10-29 2001-05-10 Stratagene Compositions et procedes utilisant des adn polymerases
WO2006028508A2 (fr) 2004-03-23 2006-03-16 President And Fellows Of Harvard College Procedes et appareil de caracterisation de polynucleotides
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US20090024331A1 (en) 2007-06-06 2009-01-22 Pacific Biosciences Of California, Inc. Methods and processes for calling bases in sequence by incorporation methods
WO2012083249A2 (fr) 2010-12-17 2012-06-21 The Trustees Of Columbia University In The City Of New York Séquençage d'adn par une synthèse utilisant des nucléotides modifiés et une détection par nanopores
US8455193B2 (en) 2008-03-28 2013-06-04 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
US8481292B2 (en) 2010-09-21 2013-07-09 Population Genetics Technologies Litd. Increasing confidence of allele calls with molecular counting
WO2013191793A1 (fr) 2012-06-20 2013-12-27 The Trustees Of Columbia University In The City Of New York Séquençage d'acides nucléiques par détection des molécules de tags dans les nanopores
WO2014074727A1 (fr) 2012-11-09 2014-05-15 Genia Technologies, Inc. Séquençage d'acide nucléique à l'aide d'étiquettes
US8822150B2 (en) 2007-02-02 2014-09-02 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple polynucleotide templates
WO2015148402A1 (fr) 2014-03-24 2015-10-01 The Trustees Of Columbia Univeristy In The City Of New York Procédés chimiques pour produire des nucléotides étiquetés
US20170044606A1 (en) 2015-08-12 2017-02-16 The Chinese University Of Hong Kong Single-molecule sequencing of plasma dna
US20170268052A1 (en) 2016-02-29 2017-09-21 Genia Technologies, Inc. Polymerase-template complexes
WO2018034745A1 (fr) 2016-08-18 2018-02-22 The Regents Of The University Of California Appel de bases de séquençage par nanopores
WO2018138237A1 (fr) 2017-01-27 2018-08-02 Roche Diagnostics Gmbh Adn en code-barres pour le séquençage de longs fragments
US10519184B2 (en) 2013-09-27 2019-12-31 Peking University 5-formylcytosine specific chemical labeling method and related applications
US20200032244A1 (en) 2017-12-21 2020-01-30 Roche Sequencing Solutions, Inc. Target enrichment by unidirectional dual probe primer extension
WO2020131759A1 (fr) 2018-12-19 2020-06-25 Roche Diagnostics Gmbh Nucléotides protégés en 3'
US11293050B2 (en) 2017-02-28 2022-04-05 Peking University Method for marking 5-formyl cytosine and use thereof in single base resolution sequencing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017039002A1 (fr) * 2015-09-04 2017-03-09 国立大学法人東京大学 Agent oxydant pour la 5-hydroxyméthylcytosine et procédé d'analyse de la 5-hydroxyméthylcytosine
JP7646850B2 (ja) * 2021-02-09 2025-03-17 エフ． ホフマン－ラ ロシュ アーゲー 核酸中のメチル化の塩基レベル検出のための方法

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000159A (en) 1974-06-28 1976-12-28 Phillips Petroleum Company Preparation of n,n-disubstituted thioamides
US5176995A (en) 1985-03-28 1993-01-05 Hoffmann-La Roche Inc. Detection of viruses by amplification and hybridization
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (fr) 1986-01-30 1990-11-27 Cetus Corp
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
WO2001032887A1 (fr) 1999-10-29 2001-05-10 Stratagene Compositions et procedes utilisant des adn polymerases
WO2006028508A2 (fr) 2004-03-23 2006-03-16 President And Fellows Of Harvard College Procedes et appareil de caracterisation de polynucleotides
US7393665B2 (en) 2005-02-10 2008-07-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US8168385B2 (en) 2005-02-10 2012-05-01 Population Genetics Technologies Ltd Methods and compositions for tagging and identifying polynucleotides
US8822150B2 (en) 2007-02-02 2014-09-02 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple polynucleotide templates
US20090024331A1 (en) 2007-06-06 2009-01-22 Pacific Biosciences Of California, Inc. Methods and processes for calling bases in sequence by incorporation methods
US8455193B2 (en) 2008-03-28 2013-06-04 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
US8481292B2 (en) 2010-09-21 2013-07-09 Population Genetics Technologies Litd. Increasing confidence of allele calls with molecular counting
US8685678B2 (en) 2010-09-21 2014-04-01 Population Genetics Technologies Ltd Increasing confidence of allele calls with molecular counting
US8722368B2 (en) 2010-09-21 2014-05-13 Population Genetics Technologies Ltd. Method for preparing a counter-tagged population of nucleic acid molecules
WO2012083249A2 (fr) 2010-12-17 2012-06-21 The Trustees Of Columbia University In The City Of New York Séquençage d'adn par une synthèse utilisant des nucléotides modifiés et une détection par nanopores
WO2013191793A1 (fr) 2012-06-20 2013-12-27 The Trustees Of Columbia University In The City Of New York Séquençage d'acides nucléiques par détection des molécules de tags dans les nanopores
WO2014074727A1 (fr) 2012-11-09 2014-05-15 Genia Technologies, Inc. Séquençage d'acide nucléique à l'aide d'étiquettes
US10519184B2 (en) 2013-09-27 2019-12-31 Peking University 5-formylcytosine specific chemical labeling method and related applications
WO2015148402A1 (fr) 2014-03-24 2015-10-01 The Trustees Of Columbia Univeristy In The City Of New York Procédés chimiques pour produire des nucléotides étiquetés
US20170044606A1 (en) 2015-08-12 2017-02-16 The Chinese University Of Hong Kong Single-molecule sequencing of plasma dna
US20170268052A1 (en) 2016-02-29 2017-09-21 Genia Technologies, Inc. Polymerase-template complexes
WO2018034745A1 (fr) 2016-08-18 2018-02-22 The Regents Of The University Of California Appel de bases de séquençage par nanopores
WO2018138237A1 (fr) 2017-01-27 2018-08-02 Roche Diagnostics Gmbh Adn en code-barres pour le séquençage de longs fragments
US11293050B2 (en) 2017-02-28 2022-04-05 Peking University Method for marking 5-formyl cytosine and use thereof in single base resolution sequencing
US20200032244A1 (en) 2017-12-21 2020-01-30 Roche Sequencing Solutions, Inc. Target enrichment by unidirectional dual probe primer extension
WO2020131759A1 (fr) 2018-12-19 2020-06-25 Roche Diagnostics Gmbh Nucléotides protégés en 3'

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. DD259857.1
LIU, Y. ET AL.: "Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution", NAT. BIOTECHNOL., vol. 37, 2019, pages 424 - 429, XP055737047, DOI: 10.1038/s41587-019-0041-2
ZHU C ET AL.: "Single-Cell 5-Formylcytosine Landscapes of Mammalian Early Embryos and ESCs at Single-Base Resolution", CELL STEM CELL, vol. 20, 2017, pages 720 - 731

Also Published As

Publication number Publication date
WO2024256358A3 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
JP7535611B2 (ja) ライブラリー調製方法ならびにそのための組成物および使用
US10711269B2 (en) Method for making an asymmetrically-tagged sequencing library
EP2905344B1 (fr) Procédé d'amplification directe á partir d'échantillons bruts d'acides nucléiques
JP6847496B2 (ja) 単一プローブプライマー伸長による標的濃縮
US8034568B2 (en) Isothermal nucleic acid amplification methods and compositions
EP2964778B1 (fr) Détection de réarrangements génomiques par capture de séquence
JP6970205B2 (ja) Ｄｎａおよびｒｎａの同時濃縮を含むプライマー伸長標的濃縮およびそれに対する向上
JP2022084645A (ja) 核酸の合成及び検出のための組成物、方法及びキット
JP2021513358A (ja) Ｄｎａ、特にセルフリーｄｎａのエピジェネティック解析の方法
WO2009102896A2 (fr) Procédés et composition pour amplification isotherme d'acide nucléique
US20180094309A1 (en) Nucleic acid retro-activated primers
US12435355B2 (en) Whole transcriptome analysis in single cells
WO2017087724A1 (fr) Procédés permettant de déterminer des profils de séquences
WO2024256358A2 (fr) Marquage accéléré de 5-formyl cytosine et utilisation dans le séquençage de méthylation d'acide nucléique
US20240279732A1 (en) Targeted next-generation sequencing via anchored primer extension
WO2006024541A2 (fr) Procede de decontamination d'adn
CN119173637A (zh) 限制酶的有用组合
US20250115960A1 (en) Nucleic acid testing method and system
WO2025210056A1 (fr) Amplification in vitro de schémas de méthylation d'adn
WO2024187012A1 (fr) Procédé de séquençage de brins natifs de régions génomiques enrichies
CA3242053A1 (fr) Procede de capture de produits du clivage de l'endonuclease crispr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24732867

Country of ref document: EP

Kind code of ref document: A2